News
AZTR
0.5314
-6.82%
-0.0389
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at AZTR last week (1109-1113)?
Weekly Report · 3d ago
Maxim Group Sticks to Their Buy Rating for Azitra Inc (AZTR)
TipRanks · 5d ago
Azitra GAAP EPS of -$0.29 misses by $0.04
Seeking Alpha · 6d ago
Azitra price target lowered to $4 from $10 at Maxim
TipRanks · 6d ago
Press Release: Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
Dow Jones · 11/12 21:30
Press Release: Azitra, Inc. Announces Q3 2026 -2-
Dow Jones · 11/12 21:30
Azitra Reports ATR-COSF Wrinkle Reduction in Skin Model
TipRanks · 11/10 13:58
Azitra To Present Pipeline Updates Including Results For ATR-COSF Program, Designed To Deliver Filaggrin Domains Into Human Skin To Reduce Appearance Of Fine Lines And Wrinkles, At BIO-Europe
Benzinga · 11/10 13:38
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models
PR Newswire · 11/10 13:30
Weekly Report: what happened at AZTR last week (1102-1106)?
Weekly Report · 11/09 09:38
Weekly Report: what happened at AZTR last week (1026-1030)?
Weekly Report · 11/02 09:38
Azitra Consensus Price Target Increased by 900% to $6.83
NASDAQ · 11/02 06:38
Azitra Amends ATR04-484 Trial, Expands Rash Eligibility
TipRanks · 10/29 12:59
Azitra expands eligibility for Phase 1/2 clinical trial of ATR-04
TipRanks · 10/29 12:42
Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors
Benzinga · 10/29 12:35
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
PR Newswire · 10/29 12:30
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/27 08:53
Azitra, Inc. Pauses ATM Program and Announces Ex Vivo Results for ATR-COSF
NASDAQ · 10/26 15:28
Azitra Highlights ATR-COSF Anti-Aging Cosmetic Study Results
TipRanks · 10/26 13:19
More
Webull provides a variety of real-time AZTR stock news. You can receive the latest news about Azitra Inc through multiple platforms. This information may help you make smarter investment decisions.
About AZTR
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.